Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2024; 12(5): 951-965
Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.951
Urinary metabolic profiles during Helicobacter pylori eradication in chronic gastritis
Wen-Ting An, Yu-Xia Hao, Hong-Xia Li, Xing-Kang Wu
Wen-Ting An, Department of Pharmacy, Shanxi Provincial People’s Hospital, Taiyuan 030012, Shanxi Province, China
Yu-Xia Hao, Department of Gastroenterology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China
Hong-Xia Li, Department of Oncology, Shanxi Provincial People’s Hospital, Taiyuan 030012, Shanxi Province, China
Xing-Kang Wu, Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, Shanxi Province, China
Co-first authors: Wen-Ting An and Yu-Xia Hao.
Co-corresponding authors: Hong-Xia Li and Xing-Kang Wu.
Author contributions: An WT contributed to conceptualization, investigation, methodology, project administration, resources, data curation, writing and formal analysis; Hao YX contributed to investigation, methodology, data curation and formal analysis; Wu XK contributed to supervision, writing, review and editing; Li HX contributed to conceptualization, methodology, supervision, funding acquisition, review and editing; all authors read and approved the final manuscript.
Supported by Shanxi Provincial Health Commission, No. 2019022.
Institutional review board statement: This study was approved by the Ethics Committee of Shanxi Provincial People’s Hospital (No. 2022-167).
Informed consent statement: All the patients voluntarily participated in the study and signed informed consent forms.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data and materials are available from the corresponding author.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Xia Li, MMed, Chief Physician, Department of Oncology, Shanxi Provincial People’s Hospital, No. 29 Shuangta Road, Taiyuan 030012, Shanxi Province, China. 345lihongxia@163.com
Received: November 3, 2023
Peer-review started: November 3, 2023
First decision: December 6, 2023
Revised: December 14, 2023
Accepted: January 22, 2024
Article in press: January 22, 2024
Published online: February 16, 2024
Processing time: 88 Days and 15.4 Hours
Abstract
BACKGROUND

Helicobacter pylori (H. pylori) infection is a major risk factor for chronic gastritis, affecting approximately half of the global population. H. pylori eradication is a popular treatment method for H. pylori-positive chronic gastritis, but its mechanism remains unclear. Urinary metabolomics has been used to elucidate the mechanisms of gastric disease treatment. However, no clinical study has been conducted on urinary metabolomics of chronic gastritis.

AIM

To elucidate the urinary metabolic profiles during H. pylori eradication in patients with chronic gastritis.

METHODS

We applied LC–MS-based metabolomics and network pharmacology to investigate the relationships between urinary metabolites and H. pylori-positive chronic gastritis via a clinical follow-up study.

RESULTS

Our study revealed the different urinary metabolic profiles of H. pylori-positive chronic gastritis before and after H. pylori eradication. The metabolites regulated by H. pylori eradication therapy include cis-aconitic acid, isocitric acid, citric acid, L-tyrosine, L-phenylalanine, L-tryptophan, and hippuric acid, which were involved in four metabolic pathways: (1) Phenylalanine metabolism; (2) phenylalanine, tyrosine, and tryptophan biosynthesis; (3) citrate cycle; and (4) glyoxylate and dicarboxylate metabolism. Integrated metabolomics and network pharmacology revealed that MPO, COMT, TPO, TH, EPX, CMA1, DDC, TPH1, and LPO were the key proteins involved in the biological progress of H. pylori eradication in chronic gastritis.

CONCLUSION

Our research provides a new perspective for exploring the significance of urinary metabolites in evaluating the treatment and prognosis of H. pylori-positive chronic gastritis patients.

Keywords: LC-MS; metabolomics; chronic gastritis; Helicobacter pylori; urinary metabolites

Core Tip: Urinary metabolomics has been used to elucidate the mechanisms of gastric disease treatment, whereas no clinical study is conducted on metabolomics of chronic gastritis. In this manuscript, we carried out LC-MS-based metabolomics to investigate urinary metabolites changes in Helicobacter pylori (H. pylori)-positive chronic gastritis treatment. Our study revealed the urinary metabolic profiles of H. pylori-positive chronic gastritis after H. pylori eradication. Integrated metabolomics and network pharmacology revealed the key proteins involved in H. pylori eradication of chronic gastritis. Our research provides a new perspective for exploring the significance of urinary metabolites in evaluating the treatment and prognosis of H. pylori-positive chronic gastritis.